RecruitingNCT05737953

Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Construction of Molecular Diagnostic Marker Models for Pancreatic Cystic Tumors Based on CfDNA Methylation Sequencing and Proteomic Analysis of Pancreatic Cystic Fluid Samples

Sponsor

Zhaoshen Li

Enrollment

100 participants

Start Date

Mar 1, 2023

Study Type

OBSERVATIONAL

Conditions

Pancreatic Neoplasms DNA Methylation Proteome

Summary

The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy. Participants will Provide post-operative cyst fluid specimens.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study aims to build a better molecular test to identify whether fluid-filled cysts in the pancreas are cancerous or benign, by analyzing fluid collected during surgery. Researchers hope to find specific biological markers that can tell these cysts apart more accurately. **You may be eligible if...** - You are 18 years old or older - Imaging tests (ultrasound, CT, or MRI) have found a cystic mass on your pancreas that is suspected to be a cystic tumor - You have agreed to have surgery to remove the cyst - You are willing to sign the informed consent **You may NOT be eligible if...** - The removed tissue does not contain cystic fluid that can be collected - You have already received cancer treatments (chemotherapy, radiation, or immunotherapy) before surgery - You took antibiotics within 1 week before surgery - You are unwilling or unable to undergo surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.